期刊文献+

羟丁基壳聚糖携载CD133抗体的复合涂层对猪髂动脉内皮细胞的影响 被引量:1

Effects of the paintcoat composited with hydroxybutyl-chitosan and CD133 antibody on the endothelial cells of swine iliac artery
下载PDF
导出
摘要 目的探讨羟丁基壳聚糖携载CD133抗体的复合涂层对体外培养的猪髂动脉内皮细胞(PIEC)生长影响和可能的机制。方法将PIEC接种于裸钴铬合金片(裸金属组)、雷帕霉素药物涂层钴铬合金片(药物涂层组)及羟丁基壳聚糖携载CD133抗体的复合涂层钴铬合金片(复合涂层组)上,光镜下观察PIEC细胞形态,以CCK-8试剂盒测定细胞增殖率,以划痕法检测细胞迁移率,以Transwell小室法定量迁移细胞,以一氧化氮(NO)硝酸还原酶试剂盒、碱性成纤维细胞生长因子(bFGF)-酶联免疫吸附(ELISA)试剂盒、内皮素(ET)-放免分析试剂盒测定NO、bFGF、ET-1的含量。结果 PIEC在复合涂层组钴铬合金片上生长良好,形态正常,与裸金属组、药物涂层组比较,复合涂层组细胞增殖率[(101.42±2.93)%vs(96.76±2.92)%、(75.74±3.51)%]、细胞迁移率[(102.80±3.43)%vs(97.38±3.04)%、(81.55±4.93)%]、细胞迁移数[(103.91±4.64)%vs(97.56±3.70)%、(82.99±5.03)%]、NO[(46.75±3.53)μmol/L vs(39.70±2.51)μmol/L、(33.15±3.46)μmol/L]及bFGF[(124.35±18.07)pg/mL vs(105.46±12.62)pg/mL、(88.47±13.37)pg/mL]均升高,但与裸金属组比较,ET-1[(30.98±7.31)pg/mL vs(47.67±9.59)pg/mL]降低,差异有统计学意义(P<0.01)。结论羟丁基壳聚糖携载CD133抗体复合涂层有助于体外培养的PIEC在钴铬合金片上的增殖和迁移,有望成为支架的新型涂层材料。 Objective To investigate the effects and possible mechanism of the paintcoat composited with hydroxybutyl-chitosan and CD133 antibody on the growth of endothelial cells of pig iliac artery(PIEC) in vitro.Methods PIEC were cultured on bare cobalt-chromium alloy film(bare metal group),rapamycin eluting cobalt-chromium alloy film(drug paintcoat group) and the paintcoat composited with hydroxybutyl-chitosan and CD133 antibody eluting cobalt-chromium alloy film(composite paintcoat group).Light microscope was introduced for morphological observation;while cell counting kit-8(CCK-8),scratch experiment and transwell chamber method were introduced for assessment of cell proliferation,cell migration and migrating cell count,respectively.Nitrate reductase kit,enzyme-linked immunosorbent assay(ELISA) kit and radioimmunoassay kit were used to measure the levels of nitric oxide(NO),basic fibroblast growth factor(bFGF) and endothelin-1(ET-1).Results Normal cells and well growth of PIEC were observed in composite paintcoat group.Compared with those in bare metal group and drug paintcoat group,in composite paintcoat group there were significant increase in cell proliferation rate,migration rate,migrating cell count,NO and bFGF.However,the level of ET-1 was significantly lower in composite paintcoat group than that in bare metal group.Conclusion The paintcoat composited with hydroxybutyl-chitosan and CD133 antibody can improve the proliferation and migration of PIEC in vitro,suggesting a new coating material for stents.
出处 《广东医学》 CAS CSCD 北大核心 2013年第15期2285-2287,共3页 Guangdong Medical Journal
基金 国家自然科学基金面上项目(编号:81071246) 山东省自然科学基金面上项目(编号:ZR2010HM081)
关键词 壳聚糖 CD133 内皮细胞 细胞生长 一氧化氮 碱性成纤维细胞生长因子 内皮素-1 chitosan CD133 endothelial cell cell proliferation nitric oxide basic fibroblast growth factorr endothelin-1
  • 相关文献

参考文献12

  • 1MEHILLI J, DIBRA A, KASTRATI A, et al. Randomized trial of paclitaxel and sirolimus - eluting stents in small coronary vessels [J]. Eur Heart J, 2006, 27(3) : 260 -266.
  • 2MENG S, LIU Z J, ZHONG W, et al. Phosphoryl choline modi- fied chitosan: appetent and safe material for ceils [ J ]. Carbohy- drate Polymers, 2007, 70( 1 ) : 82 - 88.
  • 3GARRO N, CAPODANNO D, CAMMALLERI V, et al. Very late thrombosis in acute myocardial infarction: drug - eluting versus uncoated stents [ J]. Eurolntervention, 2008, 4 (3) : 324 - 330.
  • 4HUANG Y, ONYERI S, SIEWE M, et al. In vitro characteriza- tion of chitosan -gelatin scaffoldsn for tissue engineering[J]. Bio- materials, 2005, 26(36) : 7616 -7627.
  • 5ZHANG Jing, CHEN Xi - guang, LIU Cheng - sheng, et al. In- vestigation of polymeric amphiphilic nanoparticles as antitumor drug carriers[J]. J Mater Sci: Mater Med, 2009, 20(4) : 991 - 999.
  • 6DANGA J M, SUNA D D, SHIN YA Y, et al. Temperature - re- sponsive hydroxybutyl chitosan for the culture of mesenchymal stem cells and intervertebral disk cells [ J ]. Biomaterials, 2006, 27 (3) : 406 -418.
  • 7ZHAO Qing - sheng, JI Qiu - xia, XING Ke, et al. Preparation and characteristics of novel porous hydrogel films based on chitosan and glycerophosphate [ J ]. Carbohydrate Polymers, 2009, 76 ( 3 ) : 410 -416.
  • 8MA L, GAO C, MAO Z, et al. Collagen chitosan porous scaffolds With improved biostability for skin tissue engineering[J]. Bioma- terials, 2003, 24(26) : 4833 -4841.
  • 9LLOYD JONES D M, BLOCH K D. The vascular biology of nitric oxide and its role in atherosclerosis [ J ]. Annu Rev Med, 1996, 47 : 365 - 375.
  • 10RUBIO A R, MORALES SEGUM M A. Nitric oxide, an iceberg in cardiovascular physiology : far beyond vessel tone control [ J ]. Arch Med Res, 2004, 35(1) : 1 - 11.

二级参考文献9

  • 1Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitor. Arterioslcler Thromb Vasc Biol, 2001;21 (11):1712-1719.
  • 2Siegel-Axel DI. Cerlvastatin: a cellular and molecular drug for the future7 Cell Mol Life Sci,2003;60(1):144-164.
  • 3Callahan AS 3rd. Vascular pleitropy of statlns :cllnlcal evidence and biochemical mechanisms. Curr Atheroscler Rep, 2003;5 (1) :33-37.
  • 4Kandoussi A, Martin F, Hazzan M, et al. HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. Clin Sci (Lond), 2002;103 (Suppl 48): 81S- 83S.
  • 5Ozaki K, Yamamoto T, Ishibashi T, et al. Regulation of endothelial nitric oxide synthase and endothelial-1 expression by fluvastatin in human vascular endothelial cells. Jpn J Pharmacol, 2001; 85 (2) : 147-154.
  • 6Hernandez-PO, Perez SD, Navarro AJ, et al. Effects of the 3- hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatln, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. Clin Invest,1998;101(12) :2711-2719.
  • 7Karamsetty MR, Pietras L, Kllnger JR, et al. The role of endothelin-1 in straln-related susceptibility to develop hypoxlc pulmonary hypertension in rats. Respir Physlol, 2001; 128(2) : 219-227.
  • 8Ichiki T, Takeda K, Tokunou T, et al. Downregulation of angiotension Ⅰ type 1 receptor by hydrophobic 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle ceils. Arterioscler Thromb Vasc Biol,2001;21 (12) : 1896-1901.
  • 9Shah V, Bharadwa S, Kaibuchi K, et al. Cytoskeletal organization in tro-pomyosin-mediated reversion of rastransformatiom: evidence of Rho kinasa pathway. J Oncogene, 2001 ; 20(17) : 2112-2121.

共引文献4

同被引文献29

  • 1FISCHMAN D L, LEON M B, BAIM D S, et al. Arandomized comparison of coronary-stent placement and balloonangioplasty in the treatment of coronary artery disease [ J ]. NEngl J Med, 1994,331(8): 496-501.
  • 2MITRA A K, AGRAWAL D K. In stent restenosis: bane of thestent era[J]. J Clin Pathol, 2006, 59(3): 232-239.
  • 3FERNS G A A, AVADES T Y. The mechanisms of coronaryrestenosis: insights from experimental models [J]. Int J ExpPathol, 2000, 81(2): 63-88.
  • 4MORICE M C, SERRUYS P W, BARRAGAN P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents.Five-year results of the RAVEL Trial[J]. Journal of the Americancollege of cardiology, 2007, 50(14): 1299-1304.
  • 5JAMES S K,STENESTRAND U, LINDBACK J, et al. Long-term safety and efficacy of drug-eluting versus bare-metal stentsin Sweden[J]. N Engl J Med, 2009, 360(19): 1933-1945.
  • 6KIMURA T, MORIMOTO T,NAKAGAWA Y, et al. Very latestent thrombosis and late target lesion revascularization aftersirolimus-eluting stent implantation : Five-year Outcome of thej-Cypher Registry[ J]. Circulation, 2012,125(4) : 584-591.
  • 7SILBER S, WINDECKER S, VRANCKX P, et al.Unrestricted randomised use of two new generation drug-elutingcoronary stents: 2-year patient-related versus stent-relatedoutcomes from the RESOLUTE All Comers trial [ J ]. Lancet,2011, 377(9773): 1241-1247.
  • 8STEFANINI G G, KALESAN B, SERRUYS P W, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents inpatients with coronary artery disease (LEADERS) : 4 yearfollow-up of a randomised non-inferiority trial [J]. Lancet,2011, 378(9807): 1940-1948.
  • 9OTSUKA F,VORPAHL M,NAKANO M,et al. Pathology ofsecond- generation everolimus-eluting stents versus first-generation sirolimus-and paclitaxel-eluting stents in humans[J]. Circulation, 2014,129(2): 211-223.
  • 10SHETTY R, VIVEK G, THAKKAR A, et al. Experience withbiodegradable polymer coated sirolimus-eluting coronary stentsystem in “real-life” percutaneous coronary intervention : 24-month data from the manipai-s registry [ J ]. J Clin Diagn Res ,2013,7(9): 1959.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部